Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

Stock Information for Portage Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Portage Biotech Inc.

Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024
Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program
Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS
Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.